Organization
Stichting Hemato-Oncologie voor Volwassenen Nederland
13 clinical trials
Clinical trial
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label TrialStatus: Not yet recruiting, Estimated PCD: 2028-12-15
Clinical trial
A Single Arm Phase II Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine (sc) in Adult Patients With Newly Diagnosed Acute Myeloid Leukaemia (AML) Who Are Not Considered Candidates for Intensive Treatment RegimensStatus: Recruiting, Estimated PCD: 2028-03-01
Clinical trial
A Prospective Randomized Phase I/II Trial of Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaStatus: Recruiting, Estimated PCD: 2029-03-01
Clinical trial
FeAsiBility of a Treatment Free Interval in Newly Diagnosed mUltiple myeLOma Patients Treated With DaratumUmab-Lenalidomide-DexamethaSone- the FABULOUS Study. A Nationwide Open-label Randomized Phase III Clinical Trial Comparing Daratumumab-lenalidomide-dexamethasone Continuously Versus Including a Treatment Free IntervalStatus: Not yet recruiting, Estimated PCD: 2031-01-01
Clinical trial
A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-01-18
Clinical trial
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 RearrangementsStatus: Active (not recruiting), Estimated PCD: 2024-01-30
Clinical trial
Phase II Trial of Zanubrutinib in Primary Cold Agglutinin Disease. CaZa StudyStatus: Not yet recruiting, Estimated PCD: 2027-11-01
Clinical trial
Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
Tislelizumab Plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission (TIGERR-HL). An Open Label Phase II TrialStatus: Recruiting, Estimated PCD: 2027-04-01
Clinical trial
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. A Phase II TrialStatus: Active (not recruiting), Estimated PCD: 2020-11-30
Clinical trial
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2020-12-01
Clinical trial
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Prospective, Multicenter, Phase-II Trial of Venetoclax Plus Acalabrutinib in Patients Who Have Relapsed After First Line Venetoclax + Anti-CD20 mAb Treatment for Chronic Lymphocytic Leukemia (CLL or SLL)Status: Recruiting, Estimated PCD: 2028-12-01